TSPOAP1 and non-small cell lung carcinoma: In NSCLC, BZRAP1-AS1 was lower in T2–T4 than T1 patients (38.00 (22.00–63.00) vs 58.00 (32.75–91.25), P < 0.001), N1-N3 than N0 patients (38.00 (23.00–63.00) vs 43.00 (24.00–76.00), P = 0.018) (Fig. 2D and 2G).